In recent years, the detection of cell-free DNA (cfDNA) in the blood has gained increasing importance. This circulating cfDNA contains fragments from both healthy and tumor cells. Analyzing this “liquid biopsy” aims to detect the early development and progression of malignancies with minimal invasiveness. Moreover, miRNA, methylation, and protein patterns in the blood can be detected through liquid biopsy. In the future, this form of liquid diagnostics could also be used for therapy monitoring and aftercare. Given the high cancer risk in individuals with cancer predisposition syndromes (CPS), this blood-based and less invasive method of cancer detection holds particular promise for CPS patients.<\/p>\n<\/div>
If you have any questions about the accompanying project “Liquid Biopsy”, you may find what you’re looking for in the quick links provided in the following section. Alternatively, feel free to contact us directly:<\/p>\n<\/div>
If you have any questions about the accompanying project “Liquid Biopsy”, you may find what you’re looking for in the quick links provided in the following section. Alternatively, feel free to contact us directly:<\/p>\n<\/div>
Monday-Friday from 8:00 a.m. – 1:00 p.m.<\/p>\n<\/div><\/li>
+49 511 532-9408<\/p>\n<\/div><\/li>
+49 511 532-161026<\/p>\n<\/div><\/li>